Skip to content
lifestyle.d-h.st
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
FibroBiologics, Inc.
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
September 17, 2026
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing
September 3, 2026
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
September 1, 2026
FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
August 27, 2026
FibroBiologics Regains Compliance with Nasdaq Trading Rules
August 26, 2026
FibroBiologics Appoints Leigh Steinberg to Board of Directors
August 24, 2026
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease
August 20, 2026
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets
August 11, 2026
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage
August 5, 2026
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
July 31, 2026
1
2
3
Next Page
→